Biocon Biologics out-licenses two biosimilar assets to Yoshindo

17 Oct 2022 , 09:15 AM

Biocon Biologics Ltd., a Biocon Ltd. subsidiary, said today that it has entered into a strategic out-licensing agreement with Japanese pharmaceuticals business Yoshindo Inc. for the commercialization of two of its pipeline biosimilar assets, bUstekinumab and bDenosumab, in the Japanese market.

According to the terms of the agreement, Yoshindo will have exclusive marketing rights in Japan for Biocon Biologics’ bUstekinumab and bDenosumab, for a USD 700 million# addressable market potential. Biocon Biologics will be paid an upfront licensing fee as well as future payments if specific development milestones are met over the following few years. The financial specifics of the arrangement are kept private.

Ustekinumab, a biosimilar of Stelara, is a monoclonal antibody that is used to treat psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. Denosumab, a biosimilar to Prolia, is a monoclonal antibody used to treat osteoporosis.

Biocon Biologics’ strategic agreement with Yoshindo will build on the company’s significant accomplishments in its worldwide development programmes for these two biosimilar products. Clinical trials for these two assets began in FY22, and they include both Phase 1 and Phase 3 trials, as well as sophisticated pre-clinical CMC packages.

Biocon Biologics is creating a comprehensive portfolio of 20 biosimilar assets, either individually or through strategic alliances, to supply patients with affordable biologics and allow health equity.

At around 9.18 AM, Biocon was trading at Rs261.45 up by 0.06% from its previous closing of Rs261.30 on the BSE.

For feedback and suggestions, write to us at [e-mail]